YOLFTbeta
H Lundbeck A/S

H Lundbeck A/S

HLUN-A · CO · Healthcare / Drug Manufacturers - Specialty & Generic

58.20DKK+1.30 (+2.28%)

Price History

Full chart

Market Stats

Previous Close56.90
Open57.40
Day Range56.90 – 58.60
52-Week Range31.40 – 59.80
Volume40.71K
Market Cap58.34B
P/E (TTM)14.38
Forward P/E13.09
EPS4.09
Dividend Yield2.02%
Beta0.19
50-Day Avg45.19
200-Day Avg38.19

About

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Charl van Zyl
  • Employees5.00K
  • HeadquartersOttiliavej 9, Valby, Denmark, 2500, Denmark
  • Websitehttps://www.lundbeck.com

Leadership

  • Mr. Charl van ZylPresident & CEO · b. 1967
  • Mr. Joerg HornsteinCFO & Executive VP of Corporate Functions · b. 1977
  • Dr. Per Johan Luthman Ph.D.Advisor · b. 1959
  • Dr. Tarek Samad Ph.D.Executive VP and Head of Research & Development
  • Jens HoyerVice President & Head of Investor Relations
  • Ms. Dianne HoltoExecutive Vice President of People, Culture & Sustainability · b. 1973
  • Mr. Thomas E. GibbsExecutive VP & Head of Lundbeck in United States · b. 1971
  • Prof. Johannes Rolf Streffer M.D.Senior VP & Head of Global Clinical Development · b. 1969
  • Ms. Michala Fischer-HansenExecutive VP and Head of Europe & International Markets and Operations · b. 1974
  • Ms. Tine Ostergaard HansenSenior Vice President of Corporate Affairs · b. 1975

Financials

Income Statement

Currency: DKK2004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue9.73B9.07B9.22B10.98B11.28B13.75B14.77B16.01B14.80B15.26B13.47B14.59B15.63B17.23B17.88B17.36B17.67B16.30B18.25B19.91B22.00B24.35B
Growth (%)--6.81%+1.67%+19.13%+2.70%+21.85%+7.41%+8.41%-7.53%+3.08%-11.73%+8.36%+7.13%+10.23%+3.72%-2.89%+1.78%-7.74%+11.95%+9.13%+10.51%+10.67%
Cost of Revenue932.90M1.49B1.65B2.20B1.84B2.65B2.96B3.17B3.33B4.04B4.16B5.39B4.08B3.88B3.46B3.38B4.17B3.65B3.95B4.49B4.23B4.97B
Gross Profit8.80B7.58B7.58B8.79B9.44B11.09B11.81B12.84B11.48B11.22B9.31B9.20B11.55B13.35B14.42B13.97B13.50B12.65B14.29B15.43B17.77B19.38B
Gross Margin90.41%83.60%82.15%79.99%83.72%80.69%79.97%80.22%77.54%73.54%69.11%63.03%73.89%77.48%80.67%80.50%76.42%77.62%78.35%77.48%80.78%79.58%
Operating Expense6.25B5.41B5.79B6.09B7.09B8.23B8.45B9.45B9.83B9.62B9.21B15.73B9.26B8.95B9.12B10.37B11.51B10.64B11.44B12.23B14.50B13.04B
Operating Income2.55B2.17B1.78B2.70B2.35B2.86B3.36B3.39B1.65B1.60B99.00M-6.53B2.29B4.41B5.30B3.61B1.99B2.01B2.85B3.19B3.27B6.34B
Operating Margin26.24%23.92%19.35%24.54%20.84%20.79%22.74%21.20%11.13%10.48%0.74%-44.73%14.66%25.58%29.66%20.79%11.26%12.33%15.63%16.05%14.86%26.05%
EBITDA2.82B1.85B1.47B2.31B2.44B3.67B4.53B4.62B2.06B2.77B1.64B498.00M3.58B5.62B5.29B4.78B4.88B3.44B4.39B5.06B5.71B7.34B
EBITDA Margin28.99%20.35%15.94%21.01%21.64%26.72%30.68%28.86%13.94%18.13%12.18%3.41%22.89%32.63%29.59%27.55%27.62%21.13%24.05%25.41%25.94%30.15%
Net Income1.71B2.92B2.16B3.35B2.74B2.01B2.47B2.28B1.11B855.00M-153.00M-5.69B1.21B2.62B3.91B2.67B1.58B1.32B1.92B2.29B3.14B3.19B
Net Income Margin17.56%32.23%23.41%30.53%24.25%14.60%16.70%14.26%7.48%5.60%-1.14%-39.02%7.75%15.23%21.86%15.36%8.95%8.09%10.50%11.50%14.28%13.11%
R&D1.04B1.78B1.96B2.19B2.99B3.20B3.04B3.32B2.92B2.87B2.80B8.15B2.97B2.71B3.28B3.12B4.54B3.82B3.75B3.46B4.50B4.70B
R&D as % of Total Revenue10.68%19.65%21.23%19.91%26.52%23.25%20.62%20.74%19.69%18.82%20.80%55.84%18.98%15.70%18.33%17.95%25.73%23.46%20.57%17.36%20.46%19.29%
Interest Expense23.00M795.10M564.00M724.10M1.02B178.00M205.00M212.00M85.00M281.00M465.00M478.00M307.00M97.00M29.00M86.00M249.00M214.00M165.00M97.00M154.00M541.00M
Interest Expense % of Total Revenue0.24%8.77%6.12%6.59%9.08%1.29%1.39%1.32%0.57%1.84%3.45%3.28%1.96%0.56%0.16%0.50%1.41%1.31%0.90%0.49%0.70%2.22%

Balance Sheet

Currency: DKK2004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets11.51B11.63B11.63B12.33B12.61B17.13B18.00B20.53B21.56B23.65B25.64B21.32B20.21B19.76B23.01B35.76B36.03B34.65B37.45B37.41B56.98B54.01B
Total Liabilities3.67B4.14B4.87B5.14B5.01B8.32B6.88B7.76B8.37B10.17B12.11B12.54B10.52B7.58B8.76B21.20B19.06B16.37B16.67B15.36B31.97B29.11B
Total Equity7.84B7.49B6.76B7.18B7.59B8.80B11.12B12.78B13.20B13.48B13.53B8.79B9.69B12.18B14.25B14.55B16.97B18.28B20.78B22.05B25.01B24.90B
Cash2.90B458.10M1.18B1.77B2.92B1.96B2.29B2.47B2.75B4.82B3.65B1.50B2.20B2.15B3.60B3.01B3.92B2.28B3.42B5.01B4.66B3.43B
Total Debt511.50M383.90M1.43B1.87B1.85B2.67B1.92B1.94B1.91B2.16B3.34B3.77B1.90B57.00M72.00M9.58B7.89B5.32B5.58B4.15B16.95B12.05B
Net Debt-2.39B-74.20M258.10M95.20M-1.07B711.00M-376.00M-530.00M-838.00M-2.66B-308.00M2.27B-304.00M-2.10B-3.53B6.57B3.97B3.04B2.16B-859.00M11.51B8.62B

Cash Flow

Currency: DKK2004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow2.68B2.07B1.39B2.70B2.78B3.03B3.27B3.62B2.11B3.76B1.61B197.00M3.13B4.04B5.98B2.61B3.84B2.27B3.52B4.08B3.33B4.90B
Investing Cash Flow-243.90M-634.80M-770.50M-1.10B-587.10M-5.07B-803.00M-2.69B-1.10B-1.50B-3.40B-2.84B-337.00M-1.83B-2.91B-7.75B-467.00M-610.00M-1.89B-498.00M-15.29B-611.00M
Financing Cash Flow-863.40M-1.68B-900.80M-1.01B-1.02B1.06B-2.16B-746.00M-719.00M-141.00M589.00M501.00M-2.01B-2.23B-1.61B4.55B-2.39B-3.34B-387.00M-2.08B11.63B-5.48B
Capital Expenditure313.20M00748.10M1.05B1.24B827.00M1.61B1.65B1.51B1.55B2.96B342.00M725.00M704.00M444.00M478.00M612.00M820.00M501.00M565.00M554.00M
Free Cash Flow2.36B2.07B1.39B1.96B1.73B1.80B2.44B2.01B462.00M2.25B61.00M-2.76B2.78B3.32B5.28B2.17B3.36B1.66B2.70B3.58B2.76B4.34B
Dividends Paid409.10M496.00M444.50M324.60M504.00M451.00M602.00M739.00M685.00M392.00M544.00M--483.00M1.59B2.38B815.00M497.00M397.00M576.00M694.00M943.00M
FCF to OCF88.30%100.00%100.00%72.34%62.37%59.20%74.67%55.52%21.88%59.71%3.79%-1400.51%89.06%82.08%88.23%82.98%87.54%73.06%76.70%87.72%83.01%88.69%
Dividend Paid to FCF17.30%23.94%31.89%16.59%29.07%25.11%24.69%36.73%148.27%17.46%891.80%--14.55%30.11%110.12%24.26%29.94%14.71%16.09%25.14%21.71%

Earnings

Report DateAug 17, 2022Nov 9, 2022Feb 8, 2023May 10, 2023Aug 15, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025May 13, 2026Aug 19, 2026Nov 11, 2026
EPS Estimate------------------
EPS Actual0.510.690.310.890.600.680.141.010.780.780.601.160.971.11-0.031.671.161.28
Surprise------------------
TimingPre-marketPre-marketPre-marketPre-marketPre-market----------After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap58.34B
Enterprise Value62.32B
Trailing P/E14.38
Forward P/E13.09
PEG Ratio6.51
Price / Sales2.22
Price / Book1.95
EPS4.09
Book Value28.54
Revenue (TTM)26.28B
Gross Profit (TTM)21.34B
EBITDA8.23B
Profit Margin15.69%
Operating Margin29.03%
Return on Equity15.44%
Return on Assets7.50%
Shares Outstanding199.02M
Shares Float304.43M
Beta0.19
Dividend Yield2.02%
Dividend Rate1.15
Payout Ratio41.06%

Dividends

20261×
1.15Mar 19, 2026
20251×
0.95Mar 27, 2025
20241×
0.70Mar 21, 2024
20231×
0.58Mar 22, 2023